Matches in Wikidata for { <http://www.wikidata.org/entity/Q95324197> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q95324197 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95324197 description "scientific article published on 19 May 2020" @default.
- Q95324197 description "wetenschappelijk artikel" @default.
- Q95324197 description "наукова стаття, опублікована 19 травня 2020" @default.
- Q95324197 description "գիտական հոդված հրատարակված 2020 թվականի մայիսի 19-ին" @default.
- Q95324197 name "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 name "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 type Item @default.
- Q95324197 label "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 label "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 prefLabel "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 prefLabel "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharma" @default.
- Q95324197 P1433 Q95324197-29C93084-31DB-4006-B663-84F8733E8C5E @default.
- Q95324197 P1476 Q95324197-15CF4F58-ACAD-4C0F-B66D-FF59AA2A9652 @default.
- Q95324197 P2093 Q95324197-126C1746-7446-4563-BC28-E74C52303179 @default.
- Q95324197 P2093 Q95324197-5C0C134F-1A09-4129-AD41-FF1EEC0B4EF6 @default.
- Q95324197 P2093 Q95324197-5C6A03E1-7169-4A30-88F5-BDC1301EFBE4 @default.
- Q95324197 P2093 Q95324197-77C0BD6A-35C1-4C79-B756-DF098BC2B494 @default.
- Q95324197 P2093 Q95324197-77D964FA-4B9E-4D64-90F9-956E10B06447 @default.
- Q95324197 P2093 Q95324197-7AFA240C-B6A9-4549-BD24-7F9D4BAD8C23 @default.
- Q95324197 P2093 Q95324197-81871C47-2FA1-4541-8A36-890968016DC9 @default.
- Q95324197 P2093 Q95324197-D435500B-2F8A-4F7D-AF98-E100D32DFB53 @default.
- Q95324197 P2093 Q95324197-D6A23780-EDC2-4BFF-968B-C7B2CFF38B12 @default.
- Q95324197 P2093 Q95324197-D8C2707F-6B2C-41E6-8295-CC89C4957B54 @default.
- Q95324197 P2093 Q95324197-E14BDAA7-4847-43E3-8AE2-C0D6180A259F @default.
- Q95324197 P2093 Q95324197-E7226962-E750-49E3-B325-7DCC067389E0 @default.
- Q95324197 P2093 Q95324197-EE374990-AD09-4765-8A87-1DB2FEE076B3 @default.
- Q95324197 P2093 Q95324197-F33EF904-2784-4945-90DA-561A85407C6B @default.
- Q95324197 P2093 Q95324197-F6E6999B-AC2D-4D2A-B4E3-39AF21BE4D61 @default.
- Q95324197 P31 Q95324197-BFF4BC61-85FF-44FF-910C-036A7CE57926 @default.
- Q95324197 P356 Q95324197-EB242EC3-7182-4E23-B521-264C66140D91 @default.
- Q95324197 P433 Q95324197-F9EFDF86-3C43-4E45-8982-10FF5F16621A @default.
- Q95324197 P478 Q95324197-DF2F1CEA-6FF6-4F7F-91E3-1AD2F81EC54A @default.
- Q95324197 P50 Q95324197-07E8CC97-4965-4735-BAD9-633441059051 @default.
- Q95324197 P50 Q95324197-151A04D9-6A24-4621-B39F-B2D130D6D045 @default.
- Q95324197 P50 Q95324197-23347446-6CDA-43B1-80AF-511665D13EFF @default.
- Q95324197 P50 Q95324197-2ABE4B98-947A-4B00-8AE1-A58F201B2168 @default.
- Q95324197 P50 Q95324197-8CCFF706-2F1F-4D5C-9EC5-426807058D14 @default.
- Q95324197 P577 Q95324197-0CFD2989-2981-4E46-9FA9-951E18514C55 @default.
- Q95324197 P698 Q95324197-F44AE0D9-CB5E-4DB7-A247-ABE6E3AD3498 @default.
- Q95324197 P356 JCP.19CS13169 @default.
- Q95324197 P698 32433836 @default.
- Q95324197 P1433 Q7743563 @default.
- Q95324197 P1476 "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie" @default.
- Q95324197 P2093 "American Society of Clinical Psychopharmacology" @default.
- Q95324197 P2093 "Andreas Conca" @default.
- Q95324197 P2093 "Daria Piacentino" @default.
- Q95324197 P2093 "Deanna L Kelly" @default.
- Q95324197 P2093 "Delbert G Robinson" @default.
- Q95324197 P2093 "Donald C Goff" @default.
- Q95324197 P2093 "Ekkehard Haen" @default.
- Q95324197 P2093 "Georgios Schoretsanitis" @default.
- Q95324197 P2093 "Gerald Zernig" @default.
- Q95324197 P2093 "Gerhard Gründer" @default.
- Q95324197 P2093 "John W Newcomer" @default.
- Q95324197 P2093 "Michael Paulzen" @default.
- Q95324197 P2093 "Pierre Baumann" @default.
- Q95324197 P2093 "Stephen R Marder" @default.
- Q95324197 P2093 "The Therapeutic Drug Monitoring Task Force Of The Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie" @default.
- Q95324197 P31 Q13442814 @default.
- Q95324197 P356 "10.4088/JCP.19CS13169" @default.
- Q95324197 P433 "3" @default.
- Q95324197 P478 "81" @default.
- Q95324197 P50 Q109540080 @default.
- Q95324197 P50 Q37840795 @default.
- Q95324197 P50 Q52274733 @default.
- Q95324197 P50 Q56954221 @default.
- Q95324197 P50 Q88729617 @default.
- Q95324197 P577 "2020-05-19T00:00:00Z" @default.
- Q95324197 P698 "32433836" @default.